Amarin Corporation: Business Model, SWOT Analysis, and Competitors 2026

Amarin Corporation plc stands as a leading company in Healthcare. Generating $213.65 million in annual revenue (growing -21.0% year-over-year) and carrying a market capitalization of $294.84 million, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Amarin Corporation plc continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines Amarin Corporation plc's business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating Amarin Corporation plc as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define Amarin Corporation plc's position in the Drug Manufacturers - General market today.

What You Will Learn

1. How Amarin Corporation plc generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering Amarin Corporation plc's competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who Amarin Corporation plc's main competitors are and how the company compares on key financial metrics
4. Amarin Corporation plc's key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. Amarin Corporation plc's strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $213.65 million annual revenue (TTM), +-21.0% YoY
• Market Cap: $294.84 million — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 56.6%, operating margin -4.6%, net margin -18.2%
• Free Cash Flow: Data available in latest quarterly filing
• Return on Equity: -8.2% — reflects current investment phase
• Employees: See latest annual report

Who Owns Amarin Corporation plc?

Amarin Corporation plc is publicly traded on the NASDAQ under the ticker symbol AMRN. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of Amarin Corporation plc are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

Amarin Corporation plc has approximately 21 million shares outstanding, with float shares of 0 million — the freely tradeable portion. The stock trades at $14.18 per share as of early 2026.

Amarin Corporation plc's Mission Statement

Amarin Corporation plc's strategic mission is aligned with its core business activities in the Drug Manufacturers - General sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — Amarin Corporation plc's most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For Amarin Corporation plc, the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, Amarin Corporation plc's strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does Amarin Corporation plc Make Money?

As of 2026, Amarin Corporation plc generates $213.65 million in annual revenue (growing -21.0% year-over-year), with a 56.6% gross margin and -4.6% operating margin. Market capitalization stands at $294.84 million. Here is how the company generates its revenue:

As of 2026, Amarin Corporation plc generates $213.65 million in annual revenue (growing -21.0% year-over-year), with a 56.6% gross margin and -4.6% operating margin. Market capitalization stands at $294.84 million. Here is how the company generates its revenue:

Sales of Prescription Drugs

One of the primary ways Amarin Corporation generates revenue is through the sale of prescription drugs. The company's flagship product, Vascepa, is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of severe hypertriglyceridemia. Vascepa contains a specific form of omega-3 fatty acid and has shown efficacy in reducing triglyceride levels.

Amarin sells Vascepa directly to healthcare providers, including hospitals, clinics, and pharmacies. The revenue generated from these sales is a significant source of income for the company. The demand for Vascepa has been steadily increasing due to its effectiveness and the rising awareness of the importance of managing triglyceride levels in patients.

Licensing Agreements and Collaborations

In addition to selling its own prescription drugs, Amarin Corporation also generates revenue through licensing agreements and collaborations. The company has entered into partnerships with other pharmaceutical companies to develop and commercialize new drugs or expand the therapeutic applications of existing products.

These collaborations often involve upfront payments, milestone payments based on achieving specific development or regulatory milestones, and royalties on future sales. Through these agreements, Amarin can leverage the expertise and resources of its partners while diversifying its revenue streams.

International Expansion

Amarin Corporation has been actively expanding its presence in international markets, which contributes to its revenue growth. The company has obtained regulatory approvals for Vascepa in various countries outside the United States, such as Canada and the European Union. By broadening its market reach, Amarin can tap into new patient populations and healthcare systems, thereby increasing its revenue potential.

To facilitate international expansion, Amarin may enter into distribution agreements with local partners who have established networks within the target markets. These partnerships enable the company to navigate regulatory requirements, distribution logistics, and marketing strategies specific to each country.

Conclusion

Amarin Corporati

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review Amarin Corporation plc's latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

Amarin Corporation plc Business Model Canvas

The Business Model Canvas framework provides a structured view of how Amarin Corporation plc creates, delivers, and captures value.

Key Partners: Amarin Corporation plc's key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Drug Manufacturers - General sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: Amarin Corporation plc's most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: Amarin Corporation plc's critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (N/A employees), proprietary technology, and financial resources ($302.59M in cash).

Value Propositions: Amarin Corporation plc delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Drug Manufacturers - General market.

Customer Relationships: Amarin Corporation plc maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: Amarin Corporation plc reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: Amarin Corporation plc serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: Amarin Corporation plc's major costs include cost of goods sold (43.4% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 104.6% of revenue.

Revenue Streams: Amarin Corporation plc generates revenue through its core product and service offerings.

Amarin Corporation plc Competitors

Amarin Corporation plc competes against Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE), AbbVie (ABBV), Eli Lilly (LLY) and others in the Drug Manufacturers - General segment of the Healthcare sector.

Amarin Corporation plc SWOT Analysis

A SWOT analysis examines Amarin Corporation plc's internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: Amarin Corporation plc's gross margin of 56.6% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -4.6% demonstrates disciplined cost management even at scale.

Weaknesses

• Revenue Decline: Year-over-year revenue declined 21.0%, raising questions about demand for Amarin Corporation plc's core offerings and requiring management to articulate a credible recovery path.

Opportunities

• Total Addressable Market: Amarin Corporation plc operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Amarin Corporation plc's products and services.
• Strategic Acquisitions: With $302.59M in cash and strong free cash flow generation, Amarin Corporation plc is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Amarin Corporation plc's revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Amarin Corporation plc's business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

Amarin Corporation plc enters 2026 as a leading company in Healthcare, backed by $213.65 million in annual revenue and a -18.2% net profit margin. The company's 56.6% gross margins and N/A in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in Amarin Corporation plc's core markets.

For investors and analysts, Amarin Corporation plc represents an important company to understand within the Healthcare sector. Key metrics to track include revenue growth, margin trends, and competitive positioning updates.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Amarin Corporation, SEC EDGAR – Amarin Corporation Filings, and Amarin Corporation's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. What does Amarin Corporation plc do?

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an ad

2. How much revenue does Amarin Corporation plc make?

Amarin Corporation plc generated $213.65 million in annual revenue (TTM), with -21.0% year-over-year growth.

3. What is Amarin Corporation plc's market cap?

Amarin Corporation plc's market capitalization is approximately $294.84 million as of early 2026.

4. Is Amarin Corporation plc profitable?

Amarin Corporation plc has faced profitability challenges recently. Investors should review the latest quarterly earnings reports.

5. Who are Amarin Corporation plc's competitors?

Amarin Corporation plc competes in the Drug Manufacturers - General sector against companies including Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE).

6. Does Amarin Corporation plc pay dividends?

Amarin Corporation plc does not currently pay a dividend, choosing to reinvest earnings into growth initiatives.

7. What is Amarin Corporation plc's stock ticker?

Amarin Corporation plc trades on the NASDAQ under the ticker symbol AMRN.

8. What is Amarin Corporation plc's P/E ratio?

Valuation multiples for Amarin Corporation plc can be found on major financial platforms such as Yahoo Finance, Bloomberg Terminal, or the company's latest annual report filing.

9. How many employees does Amarin Corporation plc have?

Amarin Corporation plc's employee count is disclosed in its annual filings.

10. What is Amarin Corporation plc's competitive advantage?

Amarin Corporation plc's competitive advantages include its established brand, scale in Drug Manufacturers - General, and track record of execution in the Healthcare sector.